In an era of rapid disruption, static data is no longer enough. We bridge the gap between complex market data and actionable strategy through our unique RaaS (Research-as-a-Service) framework. Explore our latest Industry Intelligence Briefings, methodology deep-dives, and expert analysis designed to provide the clarity you need for high-stakes board presentations, acquisition due diligence, and long-term strategic planning. Need specific answers? Commission a bespoke intelligence study tailored to your requirements.
Seven organizations anchor this value chain across two distinct roles: originators who manufacture largely in-house (Eli Lilly, Novo Nordisk…
Drug Product Formulation and Fill-Finish, not API peptide synthesis, is the single largest stage of the GLP-1 manufacturing value chain — an…
Global GLP-1 manufacturing capacity is racing from $45 billion to a projected $180 billion by 2031. The real capacity bottleneck - and the r…
